Preterm Delivery Clinical Trial
Official title:
Evaluation of the Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery
To demonstrate that the intramuscular administration of 17 alpha hydroxyprogesterones
caproate allows to reduce the risk of preterm delivery, in 3 high risk populations defined
by the association of an ultrasonographic cervical length egal and inferiority 26 mm between
20 and 32 weeks of gestation and:
- either a first episode of preterm labor stopped by acute tocolysis;
- either a history of late miscarriage or premature delivery or uterine malformation or
DES
- either a twin pregnancy. Therefore, a randomised, multicentre trial has been designed
with initial stratification according to these three risk groups, opened with two
parallel arms.
Objective
To demonstrate that the intramuscular administration of 17 alpha - hydroxyprogesterones
caproate allows to reduce the risk of preterm delivery, in 3 high risk populations defined
by the association of an ultrasonographic cervical length 26 mm between 20 and 32 weeks of
gestation and:
- either a first episode of preterm labor stopped by acute tocolysis;
- either a history of late miscarriage or premature delivery or uterine malformation or
DES
- either a twin pregnancy. Experimental design Prospective, randomized, multicenter,
trial with initial stratification according to three risk groups, opened with two
parallel arms.
The maximal duration for treatment will be 16 weeks for each included patient. The duration
for inclusions will be 30 months. The duration for participation of each patient will be 10
to 22 weeks. The foreseen inclusion period for this trial is from 06/01/2006 to 12/31/2008
Description Two therapeutic strategies will be compared in each risk group and attributed by
uniform randomisation.
Arm A :IM injection of 17 alpha hydroxyprogesterones caproate, 500 mg, twice a week until 36
W or until preterm delivery in high risk symptomatic group and high risk twin pregnancies
group.
IM injection of 17 alpha-hydroxyprogesterones caproate, 500 mg, once a week until 36 W or
until preterm delivery in high risk asymptomatic group.
Arm B :No treatment with 17 alpha-hydroxyprogesterones caproate. (usual management)
Presentation : Progesterone retard Pharlon 500 mg Tolerance criteria
- nausea,vomiting,
- weakness
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03304782 -
Fitbit Activity Tracker to Predict Risk of Preterm Birth
|
||
Recruiting |
NCT02420743 -
Serum Ferritin Concentration and Fetal MCA Doppler as Predictors for Preterm Delivery
|
||
Completed |
NCT01665378 -
Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes
|
N/A | |
Completed |
NCT01119963 -
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
|
Phase 2/Phase 3 | |
Completed |
NCT00141908 -
Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate
|
Phase 2 | |
Recruiting |
NCT05278130 -
Serial Screening and Treatment of Bacterial Vaginosis Trial
|
N/A | |
Terminated |
NCT03596125 -
Correction of Neonatal Glutathione by N-acetylcysteine in Pregnant Women at Risk of Premature Birth (GSH MAP)
|
Phase 2/Phase 3 | |
Recruiting |
NCT03123926 -
Spontaneous Preterm Birth Marker Test
|
N/A | |
Completed |
NCT00201643 -
A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome
|
Phase 4 | |
Completed |
NCT01353807 -
Impact of Fish Oil Supplementation in 3rd Trimester of Pregnancy on Maternal and Offspring Health
|
N/A | |
Terminated |
NCT02545127 -
Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely
|
Phase 2 | |
Completed |
NCT02371356 -
Comparing Effectiveness of Treating Depression With & Without Comorbidity to Improve Fetal Health
|
||
Active, not recruiting |
NCT01009723 -
Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers
|
N/A | |
Completed |
NCT00883324 -
Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum Versus Without Speculum
|
N/A | |
Completed |
NCT00615550 -
PREGNANT Short Cervix Trial
|
Phase 3 | |
Completed |
NCT02694679 -
Randomized Controlled Trial of Social Network Targeting in Honduras
|
N/A | |
Completed |
NCT01031017 -
Prophylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies
|
Phase 4 | |
Completed |
NCT00329914 -
Does Progesterone Prevent Very Preterm Delivery in Twin Pregnancies?
|
Phase 2 | |
Completed |
NCT01818518 -
Neonatal Outcome by Reason for Delivery
|
||
Completed |
NCT04637880 -
25- Hydroxyvitamin D Levels in Pregnancy and Effects on Pregnancy Related Disorders
|